European Union - English - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - porcine circovirus type 2 orf2 protein - immunologicals for suidae - pigs - for active immunisation of pigs with no pcv2 maternally derived antibodies from the age of 2 weeks against porcine circovirus type 2 (pcv2),

European Union - English - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - porcine circovirus type 2 orf2 protein - immunologicals for suidae - pigs - for active immunisation of pigs over the age of two weeks against porcine circovirus type 2 (pcv2) to reduce mortality, clinical signs - including weight loss - and lesions in lymphoid tissues associated with pcv2-related disease (pcvd).in addition, vaccination has been shown to reduce pcv2 nasal shedding, viral load in blood and lymphoid tissues, and duration of viraemia.onset of protection occurs as early as two weeks post vaccination and lasts for at least 17 weeks.

Philippines - English - FDA (Food And Drug Administration)

boehringer ingelheim animal health philippines, inc.; distributor: boehringer ingelheim animal health philippines, inc. - inactivated recombinant porcine circovirus type 2 (pcv2) vaccine (vet.) - suspension for injection (im) - each dose (1 ml) contains: porcine circovirus type 2 orf2 protein *rp-relative potency

Philippines - English - FDA (Food And Drug Administration)

msd animal health (phils.), inc.; distributor: msd animal health (phils.), inc. - inactivated porcine circovirus (pcv) virus vaccine (vet.) - emulsion for injection (id) - formulation: each 0.2 ml (dose) contains: porcine circovirus type 2 (orf2)> 1436 au au-antigenic units

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - porcine circovirus type 1-type 2b chimera inactivated - unknown - porcine circovirus type 1-type 2b chimera inactivated vaccine-antigen/antibody active 0.0 - active constituent

European Union - English - EMA (European Medicines Agency)

zoetis belgium sa - inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2 orf2 protein, inactivated mycoplasma hyopneumoniae, strain p-5722-3 - inactivated viral and inactivated bacterial vaccines - pigs - for active immunisation of pigs from 3 weeks of age against porcine circovirus type 2 (pcv2) to reduce viral load in blood and lymphoid tissues and fecal shedding caused by infection with pcv2.for active immunisation of pigs over the age of 3 weeks against mycoplasma hyopneumoniae to reduce lung lesions caused by infection with m. hyopneumoniae.

European Union - English - EMA (European Medicines Agency)

zoetis belgium sa - porcine circovirus recombinant virus (cpcv) 1-2, inactivated - immunologicals - pigs (piglets) - active immunisation of pigs over the age of three weeks against porcine circovirus type 2 (pcv2) to reduce viral load in blood and lymphoid tissues, and the lesions in lymphoid tissues associated with pcv2 infection, as well as to reduce clinical signs - including loss of daily weight gain, and mortality associated with post-weaning multisystemic wasting syndrome.

New Zealand - English - Ministry for Primary Industries

boehringer ingelheim animal health new zealand limited - porcine circovirus type 2 orf-2 protein - porcine circovirus type 2 orf-2 protein 0 vaccine - vaccine

European Union - English - EMA (European Medicines Agency)

zoetis belgium sa - porcine circovirus vaccine (inactivated, recombinant) - immunologicals for suidae, inactivated viral vaccines - pigs (for fattening) - for active immunisation of pigs from 3 weeks of age against porcine circovirus type 2 (pcv2) to reduce viral load in blood and lymphoid tissues and fecal shedding caused by infection with pcv2.,

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - porcine circovirus type 1-type 2b chimera inactivated; porcine circovirus type 1-type 2a chimera inactivated; thiomersal - misc. vaccines or anti sera - porcine circovirus type 1-type 2b chimera inactivated vaccine-antigen/antibody active 1.0 rp; porcine circovirus type 1-type 2a chimera inactivated active 1.0 rp; thiomersal mercury other 0.1 mg/ml - immunotherapy